Comparing Two Types of Inhaler Devices in People With Uncontrolled Asthma
Compares two inhaler devices delivering the same asthma medicines in people with poorly controlled asthma.
Plain-language title generated from the registry record
Registry title: Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler
Key facts
- Where
- Lahore, PakistanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 60 years old?
Source: NCT07372573, who can take part
Where in Pakistan
- Services Hospital LahoreLahore, PakistanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Health Sciences Lahore
- Trial code
- NCT07372573
- Record updated
- 28 January 2026
- Original description
This study compares two commonly used inhalation devices in asthma management. It focuses on evaluating how effectively PMDIs and DPIs deliver the same combination of inhaled corticosteroids and long-acting beta agonists in patients whose asthma remains poorly controlled despite treatment. The study is conducted in a tertiary care hospital setting, emphasizing real-world clinical practice and aiming to determine whether device choice influences asthma control outcomes.Read full original descriptionShow less
Effectivenes of Pressurized Meter Dose Inhaler (PMDI) Versus Dry Powder Inhaler (DPI) in Delivering Inhaled Corticosteroid and Long Acting Beta Agonist Among Patients With Uncontrolled Asthma in a Tertiary Care Hospital.
This study compares two commonly used inhalation devices in asthma management. It focuses on evaluating how effectively PMDIs and DPIs deliver the same combination of inhaled corticosteroids and long-acting beta agonists in patients whose asthma remains poorly controlled despite treatment. The study is conducted in a tertiary care hospital setting, emphasizing real-world clinical practice and aiming to determine whether device choice influences asthma control outcomes.
Inclusion: Age 14 to 60 years; Both genders; All patients with symptoms of uncontrolled asthma.
Exclusion: Patients with Hypersensitivity Pneumonitis; Patients with coexistent Interstitial Lung Disease (ILD) (confirmed on spirometry); Patients with coexistent cardiac asthma secondary to heart failure (diagnosed on echocardiography); Patients with coexistent fungal sensitization (confirmed with peripheral eosinophil count and serum IgE); Patients with coexistent Allergic Bronchopulmonary Aspergillosis (ABPA) (confirmed with HRCT and serum IgE); Patients with coexistent COPD (confirmed on spirometry).